颅内动脉瘤行血管内治疗的抗血小板聚集药物应用研究进展  

Research progress on application of antiplatelet drug in endovascular treatment of intracranial aneurysms

作　　者：王思敏 向思诗 张鸿祺[1] Wang Simin;Xiang Sishi;Zhang Hongqi(Department of Neurosurgery,Xuanwu Hospital,Capital Medical University,Beijing 100053,China)

机构地区：[1]首都医科大学宣武医院神经外科,北京100053

出　　处：《中国脑血管病杂志》2025年第2期105-112,共8页Chinese Journal of Cerebrovascular Diseases

基　　金：国家自然科学基金(62201366)。

摘　　要：颅内动脉瘤是常见的脑血管病,也是导致蛛网膜下腔出血的首要病因。随着血管内介入技术的发展,越来越多的颅内动脉瘤患者接受支架或血流导向装置置入治疗。抗血小板聚集药物已成为颅内动脉瘤行血管内介入治疗前后的常规用药。该文对常见抗血小板聚集药物的类别及其作用机制、血小板功能检测及抗血小板聚集药物的临床应用进行了归纳总结。Intracranial aneurysms are a common cerebrovascular disease and the leading cause of subarachnoid hemorrhage.With the development of endovascular interventional techniques,more and more patients are being treated with stents or flow diverter.For this reason,antiplatelet therapy has become a routinely administered drug before and after endovascular interventions.This review intends to summarize the common antiplatelet drug classes,drug mechanisms,platelet function tests and clinical applications.

关 键 词：颅内动脉瘤 血小板聚集抑制剂 血管内治疗 综述 

分 类 号：R743[医药卫生—神经病学与精神病学]